<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794363</url>
  </required_header>
  <id_info>
    <org_study_id>604763-1</org_study_id>
    <nct_id>NCT02794363</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma Injections for Vulvar Lichen Sclerosus</brief_title>
  <official_title>Autologous Platelet Rich Plasma Intradermal Injections for Vulvar Lichen Sclerosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Vulvovaginal Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Vulvovaginal Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      15 patients with biopsy proven active vulvar lichen sclerosus will be recruited by a clinic
      specializing in vulvar disorders. This study consists of a 2 week screening period and a
      12-week treatment period. Participants will receive two separate treatments of autologous
      platelet rich plasma separated by 6 weeks. A repeat biopsy will be performed 6 weeks after
      the second autologous platelet rich plasma injection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      15 patients with biopsy proven active vulvar lichen sclerosus will be recruited by a clinic
      specializing in vulvar disorders. This study consists of a 2 week screening period. A 4mm
      vulvar punch biopsy will be obtained at the initiation of the screening period to confirm
      that the participant have active lichen sclerosus. 12 weeks after the biopsy, the
      participants will receive an injection of 5cc of autologous platelet rich plasma into the
      affected vulvar skin. Six weeks later, participants will receive an additional injection of
      5cc of autologous platelet rich plasma. A repeat biopsy will be performed 6 weeks after the
      second autologous platelet rich plasma injection. The inflammation on both biopsy specimens
      will be determined by a dermatopathologist.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in inflammation on post treatment biopsies</measure>
    <time_frame>14 weeks</time_frame>
    <description>Pathologist will grade inflammation on 0-4 scale of pre and post treatment biopsies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Pruritus</measure>
    <time_frame>14 weeks</time_frame>
    <description>Participants will fill out a 10cm visual analogue scale that grade the amount of their pruritus (itching)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment</measure>
    <time_frame>14 weeks</time_frame>
    <description>The investigator will rate the severity of lichen sclerosus based on the amount of lichenification, fissures, and ulceration. This will be a 4 point scale.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Lichen Sclerosus</condition>
  <arm_group>
    <arm_group_label>Autologous platelet rich plasma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous platelet rich plasma</intervention_name>
    <description>5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.</description>
    <arm_group_label>Autologous platelet rich plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active lichen sclerosus

          -  no current treatment

          -  symptomatic 4/10 on visual analogue scale

        Exclusion Criteria:

          -  history of vulvar carcinoma or VIN
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>June 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>June 4, 2016</last_update_submitted>
  <last_update_submitted_qc>June 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Sclerosus et Atrophicus</mesh_term>
    <mesh_term>Vulvar Lichen Sclerosus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

